Local Control Outcomes of Patients With Brain Metastases From Small Cell Lung Cancer Treated With Stereotactic Radiosurgery | Synapse
April 15, 2026
Local Control Outcomes of Patients With Brain Metastases From Small Cell Lung Cancer Treated With Stereotactic Radiosurgery
Key Points
This research aims to evaluate the effectiveness of stereotactic radiosurgery (SRS) on local control outcomes in patients with brain metastases from small cell lung cancer.
Analyzed local control (LC) outcomes in patients treated with SRS for brain metastases.
Considered prior treatments like prophylactic cranial irradiation (PCI) and whole-brain radiotherapy (WBRT).
Recommended prescription dose ≥20 Gy or staged SRS when applicable.
SRS demonstrated high local control rates for small cell lung cancer brain metastases.
Overall survival (OS) was limited due to systemic disease progression.
The study indicates that higher doses or staged SRS may enhance treatment outcomes.
Abstract
SRS provides high LC for SCLC BM, including post-PCI/WBRT recurrences. OS remains limited by systemic progression. Prescription dose ≥20 Gy or staged SRS should be considered when feasible.